Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
RA Capital Management

RA Capital Management

A venture capital and private equity firm investing in public and private healthcare and life science companies.

RA Capital Management is a venture capital and private equity firm investing in public and private healthcare and life science companies that is headquartered in Boston, Massachusetts and was founded in 2004 by Richard Aldrich.

Investments

As of December 2019, RA Capital Management has made 114 investments, lead 28 investments, and made a total of 62 exits. Notable investments made by Ra Capital Management (as of December 2019) include: Audentes Therapeutics, 89bio, Bluebird Bio, Precision BioSciences, Moderna Therapeutics, Peloton Therapeutics, Orchard Therapeutics, Phathom Pharmaceuticals, Global Blood Therapeutics, and AveXis.

Investment funds
RA Capital Nexus Fund

On July 15, 2019 RA Capital Management announced raising $308 million for their RA Capital Nexus Fund. The fund increases the firms deal capiacity to $1 billion, and the total managed assets to about $2.5 billion. The firms plans on using the fund to invest in companies working on products and services realted to neurology, oncology, cardiovascular disease, and rare diseases.

Timeline

Invested in

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
BioSpace
June 28, 2021
BioSpace
POINT Biopharma Inc., a global radiopharmaceutical company dedicated to advancing precision radioligand therapy for the treatment of cancer, announced the appointment of Myra Herrle, Ph.D., R.Ph., RAC as Executive Vice President of Regulatory Affairs.
Kyle LaHucik
June 17, 2021
FierceBiotech
LENZ Therapeutics re-emerged Thursday after saying goodbye to the name Presbyopia Therapies. The company also announced a new CEO and a fresh start with $47 million in funding to bring its aceclidine eye drop for improving near vision to market with an FDA submission.
BioSpace
May 17, 2021
BioSpace
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, announced the appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer.
Gené Teare
May 6, 2021
Crunchbase News
Global venture funding in April 2021 continued at a strong pace. Venture capital and alternative investors invested $48 billion last month, according to Crunchbase data, marking the second-highest month for investments in private companies.
Heather Landi
May 3, 2021
FierceHealthcare
Swedish digital health startup Kry hauled in about $316 million to scale up its telehealth platform, RapidDeploy pulled in $29 million to empower 911 centers with data and more funding news in April.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.